March 25, 2025 10:57 AM EDT

Kezar toplines small Phase 2a dataset in autoimmune liver disease

Max Gelman

Senior Editor

Kezar reported new data Tuesday morning from a small Phase 2a study in autoimmune hepatitis, or AIH, a condition where the immune system attacks the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Kezar toplines small Phase 2a dataset in autoimmune liver disease

Max Gelman

Senior Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

US drugs rely heavily on ingredients made overseas, new report shows

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

Biotech seed rounds sink to lowest level in years as industry slump drags on

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Kezar toplines small Phase 2a dataset in au­toim­mune liv­er dis­ease

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Kezar toplines small Phase 2a dataset in autoimmune liver disease